lncRNA MT1JP Suppresses Biological Activities of Breast Cancer Cells in vitro and in vivo by Regulating the miRNA-214/RUNX3 Axis.
MCF-7
MDA-MB-231
MT1JP
invasion
migration
proliferation
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
12
2019
accepted:
01
04
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
The purpose of our research was to evaluate MT1JP in breast cancer. For clinical purpose, tissues were collected, and a correlation analysis ofMT1JP and miRNA-214 gene expressions was conducted. Using an in vitro study, MDA-MB-231 and MCF-7 cell lines were used as research objects in our research. Colony, flow cytometry, TUNEL, transwell, adhesion and wound healing assay were used to discuss the biological activities of the cells. In an in vivo study, tumor weight and volume were measured, and cell apoptosis was measured by TUNEL assay. The relative mechanism's proteins were evaluated by Western blotting or immunohistochemistry assay. Compared with adjacent tissues, MT1JP and miRNA-214 gene expressions were significantly different (P<0.001, respectively). By in vitro and in vivo studies, the biological activities of the cells were significantly decreased in MDA-MB-231 and MCF-7 cell lines with MT1JP overexpression. The relative mechanism was correlated with miRNA-214/RUNX3 axis. The overexpression of MT1JP suppresses the biological activities of breast cancer cells by regulation miRNA-214/RUNX3 axis in vitro and vivo study.
Identifiants
pubmed: 32581560
doi: 10.2147/OTT.S241503
pii: 241503
pmc: PMC7280253
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5033-5046Informations de copyright
© 2020 Ouyang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Cancer Res Clin Oncol. 2011 Dec;137(12):1823-30
pubmed: 21922326
Cancer. 2012 Nov 15;118(22):5507-17
pubmed: 22576578
PLoS Biol. 2018 Oct 8;16(10):e2004204
pubmed: 30296263
Cancer Invest. 2015 Apr;33(4):121-5
pubmed: 25664646
Cell Physiol Biochem. 2018;50(2):473-488
pubmed: 30308479
J Breast Cancer. 2018 Sep;21(3):277-287
pubmed: 30275856
J Cell Physiol. 2019 Feb 20;:
pubmed: 30786017
Biomaterials. 2017 Dec;149:98-115
pubmed: 29024838
Cancer. 2014 Aug 1;120(15):2299-307
pubmed: 24737648
Oncogene. 2012 Oct 25;31(43):4577-87
pubmed: 22266873
Cancer Discov. 2011 Oct;1(5):391-407
pubmed: 22096659
J Pathol. 2015 Dec;237(4):520-31
pubmed: 26239696
PLoS One. 2014 Jan 24;9(1):e86917
pubmed: 24475196
FEBS Lett. 2020 Jan;594(2):227-239
pubmed: 31545515
PeerJ. 2019 Oct 7;7:e7686
pubmed: 31608167
Cell Physiol Biochem. 2018;46(6):2445-2459
pubmed: 29742512
Mol Cancer. 2018 May 2;17(1):87
pubmed: 29720189
Cancer Biomark. 2017 Jul 4;19(4):411-418
pubmed: 28582840
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):6002-6007
pubmed: 30280783
Int J Prev Med. 2019 Jul 19;10:127
pubmed: 31531217
Cell Physiol Biochem. 2018;50(1):52-65
pubmed: 30326469
Mol Cell Biol. 2006 Jun;26(12):4474-88
pubmed: 16738314
Oncol Rep. 2011 Aug;26(2):349-57
pubmed: 21567090
Hum Pathol. 2011 Dec;42(12):1862-72
pubmed: 21658745
Med Sci Monit. 2019 Jul 10;25:5114-5126
pubmed: 31342947
J Cell Physiol. 2019 Nov;234(11):19553-19564
pubmed: 31066040
Oncogene. 2007 Oct 25;26(49):7038-48
pubmed: 17486061
Life Sci. 2009 Feb 27;84(9-10):311-20
pubmed: 19159630
Biomed Pharmacother. 2019 Oct;118:109369
pubmed: 31545229
Int J Cancer. 2011 Oct 1;129(7):1586-98
pubmed: 21128246
Onco Targets Ther. 2016 Aug 26;9:5339-47
pubmed: 27616890
J Dairy Sci. 2018 Dec;101(12):11061-11073
pubmed: 30268606
Cancer Sci. 2008 Jul;99(7):1334-40
pubmed: 18410404
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Oncotarget. 2016 Mar 29;7(13):15787-800
pubmed: 26909858
Medicine (Baltimore). 2018 May;97(21):e10394
pubmed: 29794726